BrightSpring Health Services announces Onco360 as its national pharmacy partner for advanced cancer and blood disease medications.
Quiver AI Summary
BrightSpring Health Services announced that its specialty pharmacy partner, Onco360®, has been designated as the national pharmacy partner for several newly approved medications aimed at treating advanced cancers and blood disorders. BrightSpring's President and CEO, Jon Rosseau, expressed pride in Onco360's efforts to distribute innovative therapies that improve outcomes for patients with previously untreatable diseases. The newly approved medications include treatments for breast cancer, myelodysplastic syndromes, specific brain tumors, paroxysmal nocturnal hemoglobinuria, metastatic esophageal carcinoma, non-small cell lung cancer, and acute leukemias. BrightSpring provides integrated health solutions across various service lines to support complex patient needs. Onco360, the largest independent oncology pharmacy in the U.S., specializes in meeting the unique requirements of cancer treatment.
Potential Positives
- BrightSpring's partnership with Onco360® as a national pharmacy partner positions the company at the forefront of advanced cancer and blood disease treatment, enhancing its reputation in the healthcare sector.
- The selection of Onco360® to distribute multiple breakthrough therapies underscores BrightSpring's commitment to improving patient outcomes in complex health conditions, potentially attracting more clients looking for specialized care.
- The announcement highlights BrightSpring's extensive reach, providing integrated health solutions in all 50 states, which may enhance its market presence and operational credibility.
- Bringing innovative treatments to market supports BrightSpring's mission to serve diverse populations, aligning with an increasing demand for specialized healthcare services.
Potential Negatives
- The press release may indicate a reliance on Onco360 for critical cancer treatments, potentially exposing BrightSpring to risks if Onco360 faces operational challenges or reputational issues.
- The focus on the achievements of Onco360 may detract attention from BrightSpring's own business activities, raising questions about their independent contributions to the healthcare sector.
- No specific financial metrics or forecasts are provided, which may leave stakeholders concerned about the economic implications of this partnership and the overall business outlook for BrightSpring.
FAQ
What recent achievement has Onco360® accomplished?
Onco360 has been selected as the national pharmacy partner for several medications approved for advanced cancers and blood diseases.
Which medications has Onco360® been selected to distribute?
Onco360 distributes ITOVEBI™, Rytelo™, Voranigo®, PIASKY®, Tevimba®, LAZCLUZE™, Revuforj®, and Vyloy®.
What is BrightSpring Health Services' role?
BrightSpring Health Services partners with Onco360 to enhance access to innovative treatments for patients with complex health needs.
Where is Onco360® headquartered?
Onco360 is headquartered in Louisville, Kentucky, and operates as the largest independent Oncology Pharmacy in the nation.
How does Onco360® support cancer treatment?
Onco360 provides clinical support services and specialized pharmacy solutions tailored to the needs of oncologists, patients, and healthcare facilities.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$BTSG Insider Trading Activity
$BTSG insiders have traded $BTSG stock on the open market 3 times in the past 6 months. Of those trades, 2 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $BTSG stock by insiders over the last 6 months:
- GROUP PARTNERSHIP L.P. KKR purchased 11,619,998 shares.
- PHOENIX AGGREGATOR L.P. KKR purchased 11,619,998 shares.
- BOOTS ALLIANCE, INC. WALGREENS sold 11,619,998 shares.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$BTSG Hedge Fund Activity
We have seen 83 institutional investors add shares of $BTSG stock to their portfolio, and 47 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WALGREENS BOOTS ALLIANCE, INC. removed 11,619,998 shares (-33.3%) from their portfolio in Q3 2024
- KOHLBERG KRAVIS ROBERTS & CO. L.P. added 11,619,998 shares (+14.3%) to their portfolio in Q3 2024
- NORGES BANK added 5,165,027 shares (+inf%) to their portfolio in Q2 2024
- FMR LLC added 2,664,582 shares (+17.2%) to their portfolio in Q3 2024
- 8 KNOTS MANAGEMENT, LLC removed 2,433,943 shares (-29.6%) from their portfolio in Q3 2024
- SILVERCREST ASSET MANAGEMENT GROUP LLC removed 2,030,865 shares (-60.9%) from their portfolio in Q3 2024
- TEACHER RETIREMENT SYSTEM OF TEXAS removed 1,834,565 shares (-100.0%) from their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
LOUISVILLE, Ky., Nov. 26, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services (“BrightSpring” or “BrightSpring Health Services”) (NASDAQ: BTSG) is proud of its specialty pharmacy partner, Onco360 ® , for being selected as the national pharmacy partner for multiple medications approved to treat advanced cancers and blood disease.
“Our partner Onco360 is rapidly bringing innovative medicines and treatments to market to help improve the lives of patients living with once untreatable, rare diseases,” said BrightSpring’s President and CEO, Jon Rosseau. “We are proud of their work to distribute breakthrough therapies and treatments to life-threatening diseases, expanding available care options, and extending the lives of many patients facing rare cancers and blood diseases.”
Onco360 ® , the nation’s leading independent specialty pharmacy, has been selected as a pharmacy partner for the following medications:
- ITOVEBI™ is approved to treat certain types of locally advanced or metastatic breast cancer.
- Rytelo™ is approved for the treatment of adult patients with myelodysplastic syndromes, a group of cancers that occur when the bone marrow produces immature blood cells.
- Voranigo ® is approved for the treatment of adults and pediatric patients 12 years and older with certain types of brain tumors called astrocytoma or oligodendroglioma with an isocitrate dehydrogenase-1 (IDH1) or isocitrate dehydrogenase-2 (IDH2) mutation.
- PIASKY ® is approved to treat adults and pediatric patients 13-years and older that have paroxysmal nocturnal hemoglobinuria, a life-threatening blood disorder that causes the destruction of red blood cells.
- Tevimbra ® is approved for the treatment of adult patients with metastatic esophageal cell carcinoma after prior systemic chemotherapy.
- LAZCLUZE™ is approved as a first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer.
- Revuforj ® is the first and only menin inhibitor approved for the treatment of relapsed or refractory acute leukemias with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients.
- Vyloy ® is currently the first and only approved monoclonal antibody specifically designed to target gastric tumor cells that express the biomarker claudin (CLDN) 18.2.
About BrightSpring Health Services:
BrightSpring Health Services provides complementary and integrated home- and community-based pharmacy and health solutions for complex populations in need of specialized and/or chronic care. Through the Company’s service lines, including pharmacy, home health care and primary care, and rehabilitation and behavioral health, we provide comprehensive care and clinical solutions in all 50 states to over 400,000 customers, clients and patients daily.
About Onco360 Oncology Pharmacy:
Onco360 is the nation’s largest independent Oncology Pharmacy and clinical support services company. Onco360 was founded in 2003 to bring together the stakeholders involved in the cancer treatment process and serve the specialized needs of oncologists, patients, hospitals, cancer centers of excellence, manufacturers, health plans, and payers. It dispenses nationally through its network of URAC-, and ACHC-accredited Specialty Pharmacies. Onco360 is headquartered in Louisville, Kentucky, and is a flagship specialty pharmacy brand of PharMerica Corporation, a leading institutional pharmacy, specialty infusion, and hospital services company servicing healthcare facilities in the United States. For more information about Onco360, please visit
Onco360.com
.
Media Contact
Leigh White
[email protected]
502.630.7412
